PatientsVille.com Logo


Reyataz Medical Research Studies

Up-to-date List of Reyataz Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Reyataz Medical Research Studies

Rank Status Study
1 Recruiting Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression
Condition: Human Immunodeficiency Virus
Interventions: Drug: Atazanavir, ritonavir, lamivudine;   Drug: Atazanavir, Ritonavir, 2 NRTIs
Outcome Measure: Proportion of patients with viral load < 50 copies/mL
2 Recruiting Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
Condition: HIV Infection
Intervention: Drug: atazanavir 300mg boosted with ritonavir 50 mg
Outcome Measures: Pharmacokinetics;   adverse events
3 Unknown  Atazanavir and Lamivudine for Treatment Simplification
Condition: HIV Infections
Interventions: Drug: Lamiduvine (Epivir);   Drug: Atazanavir (Reyataz);   Drug: Ritonavir (Norvir)
Outcome Measures: proportion of patients with virological failure (two consecutive measures of HIV-RNA higher than 50 copies/mL or a single measure higher than 1000 copies/mL) within 48 weeks at intention-to.treat analysis;   Time to virological failure at survival analysis;   Proportion of patients with viral load lower than 50 copies/mL at 48 weeks at the intention to treat analysis;   Evolution of CD4 cell count during the 48 weeks;   Evolution of adherence and quality of life during the 48 weeks;   Evolution of atazanavir plasma concentrations during the 48 weeks;   Change of metabolic parameters at 48 weeks;   Change of the results of neurocognitive tests at 48 weeks;   Change of bone density and of subcutaneous fat at 48 weeks
4 Not yet recruiting Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
Conditions: HIV Infection;   Osteopenia
Interventions: Drug: raltegravir and atazanavir and ritonavir;   Drug: tenofovir/emtricitabine and atazanavir and ritonavir
Outcome Measures: Variations from baseline in DEXA-measured bone mineral density (t-score, spine and femur);   variations from baseline in CTX (C-terminal telopeptide of type I collagen) and OC (Osteocalcin);   To assess the variation in renal function
5 Unknown  SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
Conditions: HIV Infections;   Lipodystrophy
Interventions: Drug: atazanavir (Reyataz);   Drug: ritonavir (Norvir)
Outcome Measure:
6 Unknown  Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers
Condition: Atazanavir
Interventions: Drug: atazanavir;   Drug: Atazanavir(ATZ) and Tenofovir(TDF);   Drug: Atazanavir(ATZ) + Ritonavir;   Drug: atazanavir(ATZ) + tenofovir(TDF) + ritonavir
Outcome Measures: Pharmacokinetic analysis;   Pharmacokinetic evaluation
7 Recruiting Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
Conditions: HIV-1 Infection;   Immunosuppression-related Infectious Disease
Interventions: Drug: DARUNAVIR;   Drug: ATAZANAVIR
Outcome Measures: Viral load of HIV-1 < 50 cp/ml;   • Proportion of subjets with virologic efficacy;   • Proportion of subjects with confirmed virologic failure;   Viral lod of HIV-1 on seminal fluid;   Immunologic response;   Differenciation and activation of lymphocytes;   Pharmacokinetics evaluation of the drugs in plasma;   Pharmacokinetic evaluation of the drugs in semen;   • Evaluate the relationship of bilirubinemia with atazanavir;   Fasting glucose, lipids and insulin;   Clinic and biologic tolerance;   Sexual behaviour;   Adherence patient satisfaction
8 Recruiting Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
Condition: Human Immunodeficiency Virus
Interventions: Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV);   Drug: tenofovir/emtricitabine (TDF/FTC);   Drug: Atazanavir (ATV);   Drug: Ritonavir;   Procedure: Phlebotomy
Outcome Measure: Clearance estimates for each drug, adjusted for age and frailty
9 Unknown  Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
Condition: HIV Infections
Intervention: Drug: Raltegravir and Atazanavir
Outcome Measures: Evaluation of the proportion of patients who maintain plasma HIV viral load measurements < 400 copies/ml at week 4, 8, 12, 16, 24, 36 and 48 weeks after switching to Raltegravir and Atazanavir;   Evaluation of the proportion of patients who have plasma HIV viral load measurements <50 copies/ml at week 4, 8, 12, 16, 24, 36 and 48 weeks after switching to Raltegravir and Atazanavir;   Time to virologic failure (defined as 2 consecutive VL measurements > 400 copies/ml on 2 separate clinic visits within 4 weeks);   Assessment of CD4 cell count changes at 4, 8, 12, 16, 24, 36 and 48 weeks after switching to Raltegravir and Atazanavir;   Assessment of lipid changes after change in regimen;   Determination of incidence, genotypic and phenotypic resistance patterns, in particular to Raltegravir and Atazanavir, in patients in the event of rebound viremia;   Patient adherence to a regimen of Raltegravir and Atazanavir
10 Recruiting Korean Post-marketing Surveillance for Reyataz®
Condition: HIV-1
Intervention: Drug: No Intervention
Outcome Measures: Adverse events occurrence;   Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) level before and after drug administration;   CD 4 T-cell count before and after drug administration;   Overall efficacy evaluation by investigator's discretion
11 Unknown  Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Raltegravir;   Drug: Atazanavir/Ritonavir
Outcome Measures: Incidence of grade 3-4 liver function test (LFT) elevations;   Viral suppression;   Immunologic response;   Overall safety in patients with mild to moderate hepatic impairment;   Outpatient retention rates;   QTc interval changes
12 Unknown  Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment
Condition: HIV Infections
Interventions: Drug: lamivudine, abacavir , ritonavir, atazanavir;   Drug: emtricitabine, tenofovir, ritonavir, atazanavir
Outcome Measures: antiretroviral effect over 48 weeks;   The immunologic effects from baseline at the 48th and 144th week;   Reasons of treatment failure by 144th week;   Adverse events and their rate of incidence by 144th week
13 Not yet recruiting RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients
Condition: Chronic Infection With HIV
Interventions: Drug: Ritonavir boosted Atazanavir;   Drug: Raltegravir;   Drug: TDF/FTC (or 3TC)
Outcome Measures: Proportion of subjects with plasma HIV-1 RNA below the limit of detection (<50 copies/mL)in an intention to treat (exposed) analysis.;   Proportion of subjects with SAEs and proportion with AEs leading to discontinuation.;   Change from baseline on viral load;   Change from baseline in lipid profile and renal function;   Change from baseline in inflammation markers
14 Recruiting Study to Evaluate a HIV Drug for the Treatment of HIV Infection
Condition: HIV-1 Infection
Interventions: Drug: BMS-955176;   Drug: Placebo matching with BMS-955176;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir;   Drug: Emtricitabine
Outcome Measures: Change in plasma HIV-1 RNA levels from baseline (Day 1-predose) on Day 11 with monotherapy;   Safety based on frequency of Adverse events (AEs), serious AEs, discontinuations due to AEs, findings of marked abnormalities in vital signs, clinical laboratory tests, ECG readings and physical examinations;   Time course of the change from baseline in plasma log10 HIV-1 RNA levels and the time of maximum decrease during the 10-day monotherapy and combination therapy of BMS-955176 with Atazanavir (ATV) +/- Ritonavir (RTV);   Change from baseline in CD4+ and CD8+ lymphocyte counts and percentages following monotherapy and combination therapy of BMS-955176 with ATV +/- RTV in HIV-1 infected subjects;   Maximum observed plasma concentration (Cmax) of BMS-955176;   Observed concentration at 24 hours postdose (C24) of BMS-955176;   Time of maximum observed plasma concentration (Tmax) of BMS-955176;   Trough observed plasma concentration (Ctrough) of BMS-955176;   Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-955176;   Accumulation Index (AI), calculated as ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-955176;   Apparent total body clearance (CLT/F) of BMS-955176;   Terminal Plasma half-life (T-Half)-after last dose only of BMS-955176;   Degree of Fluctuation (DF), calculated as steady state (Cmax-C24) / (AUC(TAU) / 24) of BMS-955176;   Average steady-state plasma concentration (Css-av), calculated as AUC(TAU) / TAU of BMS-955176
15 Recruiting Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Interventions: Drug: ATV;   Drug: DRV;   Drug: Cobicistat;   Drug: BR
Outcome Measures: Plasma pharmacokinetics (PK) parameters of ATV and DRV (as measured by AUCtau) at Day 10;   Incidence of treatment-emergent adverse events and laboratory abnormalities;   PK parameters of ATV and DRV (as measured by Ctau, Cmax, CL/F) and cobicistat (as measured by AUCtau, Cmax, Ctau, CL/F, and Vz/F);   Percentage of participants with plasma HIV-1 RNA < 50 copies/mL;   The time to pure virologic failure;   Change from baseline in log10 HIV-1 RNA (copies/mL);   Change from baseline in CD4+ cell count (cells/µL);   Acceptability (assessed by adherence) and palatability of cobicistat;   Change from baseline in CD4 percentage;   Change from baseline in CD4 percentage in participants < 5 years old
16 Unknown  Pilot Study of a Raltegravir Based NRTI Sparing Regimen
Conditions: Acquired Immune Deficiency Syndrome;   AIDS;   Human Immunodeficiency Virus;   HIV Infections
Interventions: Drug: Raltegravir;   Drug: Atazanavir;   Other: Standard treatment regimen
Outcome Measures: Virologic Failure: Primary comparisons is regimen a. versus b. for the proportion of patients remaining <50 copies HIV RNA/ml at week 48.;   Proportion of patients with < 400 copies HIV RNA/mL at week 48; Change in CD4+ cell count at weeks 24 and 48; proportion of patients with new HIV disease progression event; changes in fasted lipid and glycemic parameters changes in renal function
17 Unknown  Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)
Condition: HIV Infections
Intervention: Drug: ATV/r
Outcome Measures: noninferiority;   viral load;   serious adverse events
18 Recruiting A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir/abacavir/lamivudine FDC;   Drug: Atazanavir;   Drug: Ritonavir;   Drug: Tenofovir/emtricitabine FDC
Outcome Measures: Proportion of subjects with plasma HIV-1 ribonucleic acid (RNA) <50 copies/milliliter (c/mL) at Week 48;   Proportion of subjects with plasma HIV-1 RNA <50 c/mL and <400 c/mL over time;   Absolute values and change from Baseline in plasma HIV-1 RNA over time;   Absolute values and changes from Baseline in CD4+ cell counts over time;   Incidence of disease progression;   Incidence and severity of adverse events (AEs) and proportion of subjects who discontinue treatment due to AEs;   Incidence, severity, absolute values and changes over time in laboratory parameters abnormalities;   Change from Baseline in fasting lipids and glucose;   Changes from Baseline in renal and bone markers;   Change from Baseline in health related quality of life and treatment satisfaction;   Incidence of treatment emergent genotypic and phenotypic resistance in subjects who meet confirmed virologic withdrawal criteria
19 Recruiting The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception
Conditions: Pregnancy;   HIV;   AIDS
Intervention: Drug: Norethindrone acetate
Outcome Measure: AUC norethindrone
20 Unknown  Safety Study of Raltegravir in HIV/HCV Co-infected Patients
Conditions: HIV;   Hepatitis C
Interventions: Drug: raltegravir;   Drug: Atazanavir/ritonavir
Outcome Measures: Primary objective;   Secondary objectives

These studies may lead to new treatments and are adding insight into Reyataz etiology and treatment.

A major focus of Reyataz research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Reyataz